{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 102,
  "pageCount": 366,
  "prevPage": 101,
  "nextPage": 103,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses Q&A format to frame expert opinion as a critique of Bioprojet's claims.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/102",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-102",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "He also expressed skepticism of pitolisant’s published hERG/cardiac safety study, calling the methodology old-school and primitive, and stated that he “would be surprised” if pitolisant “would get a passing grade” now on cardiovascular safety.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd2-307e1d697026",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "list",
      "text": "Q: “I don't even know if they've done those studies because when I tried to find any published PK studies from Bioprojet, there's almost nothing out there.”\nA: “To be honest, the fact that I can tell you—I can only tell you what I've seen [in public] at meetings. You can tell what the level of interest we had in that particular type of structure was. If we felt that was the bee’s knees, and that was the way to go, I think it's possible if we wanted to get ahead of another company—”\nQ: “You would have licensed it in a nanosecond, like any big pharma company.”\nA: “Now you're touching on areas I can't talk about.” –Longtime senior scientist at Johnson & Johnson, with global leadership roles in neuroscience",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9efbb770-522e-4070-b006-9dd112b3143b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.07,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "We speculate that JNJ evaluated licensing or buying pitolisant and ran for the hills",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27d626f3-ebb1-4b3d-a299-dbc88413f475",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.86,
        "x": 0.07,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "“Would be surprised” if pitolisant “would get a passing grade” now on CV safety; purported hERG assays are primitive\n“When the compound was discovered, which we'll say in 2005. In those days, there had been a lot of drugs withdrawn from the market because of what they call Torsades de Pointes...when that happens, it's pretty quick you're going to die shortly afterwards. So, there are a number of compounds. Astemizole and Seldane, the antihistamine, and there were many others. There was a compound from Pfizer as well. They all saw what's called QT prolongation, and then they were able to associate that with the hERG channel. So, everybody then becomes concerned about, well, we have to have a hERG-binding screen in our drug-drug discovery efforts because we don't really want to launch a compound with all these problems. In the intervening years, hERG is a component—and they have high throughput patch plant methods now—so, your hERG component, your measurement is important. But with the advances in sort of molecular biology, you can now use cardiomyocytes, beating cardiomyocytes. And so, those assays have become just as important. So, hERG is now just one component of cardiovascular safety. What a company—and what I would do in my laboratory—we would have much more sophisticated cardiovascular safety. I would be surprised, based on what I've heard about pitolisant, if it would get a passing grade in what we would do, say, in 2022. So, there were a whole lot of changes happening between 2002 and now to make sure that the cardiovascular risk of your compounds is minimal or at least it's manageable.” -Ex-longtime senior scientist at Johnson & Johnson, with global leadership roles in neuroscience",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "343515d6-ff3b-4776-bab5-88d07e020c24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "He hinted - in our opinion - that J&J could easily have licensed pitolisant if Bioprojet’s claims were true but ran for the hills: “if we had been super, super interested, we could have done it...but we weren't because we felt we had much better compounds - we knew we had better compounds”; “if we felt that was the bee’s knees....” He also expressed skepticism of pitolisant’s published hERG/cardiac safety study, calling the methodology old-school and primitive, and stated that he “would be surprised” if pitolisant “would get a passing grade” now on cardiovascular safety.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bc0c6fe-9751-4753-8042-74e70ca4e915",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“To be honest, the fact that I can tell you—I can only tell you what I've seen [in public] at meetings. You can tell what the level of interest we had in that particular type of structure was. If we felt that was the bee's knees, and that was the way to go, I think it's possible if we wanted to get ahead of another company—” — Longtime senior scientist at Johnson & Johnson, with global leadership roles in neuroscience",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd2-36b7b9f064cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.07,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9b60442-8da7-43b5-9b83-a631fab244fc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}